BIOMAT Database Logo BIOMAT Database Logo

Antimalarial activity of sera from subjects taking HIV protease inhibitors. 2007

Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.

Synergy between HIV and malaria is being increasingly recognized. We examined the antimalarial activity of sera from subjects receiving chloroquine, no drugs or HAART. Sera from subjects taking ritonavir-boosted saquinavir or lopinavir significantly inhibited parasite growth (median of 55 and 69% inhibition, respectively). These results indicate that patients on protease inhibitors may be afforded some protection from malaria. The clinical relevance of these observations will require confirmation in controlled studies in malaria-endemic regions.

UI MeSH Term Description Entries
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016778 Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations. Plasmodium falciparum Malaria,Malaria, Plasmodium falciparum
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Stage-specific antimalarial activity of cysteine protease inhibitors.
May 2002, Biological chemistry,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.
March 2010, Antimicrobial agents and chemotherapy,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Antileishmanial activity of HIV protease inhibitors.
July 2005, International journal of antimicrobial agents,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
July 2005, Antimicrobial agents and chemotherapy,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Protease inhibitors and antimalarial effects.
January 1984, Progress in clinical and biological research,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Antimalarial activity of HIV-1 protease inhibitor in chromone series.
December 2014, Bioorganic chemistry,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: a case series.
July 1999, Haemophilia : the official journal of the World Federation of Hemophilia,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro.
January 2010, The American journal of tropical medicine and hygiene,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Synthesis and antimalarial activity of thioetherhydroxyethylsulfonamides, potential aspartyl protease inhibitors, Part 3.
November 2011, European journal of medicinal chemistry,
Andrew M Redmond, and Tina Skinner-Adams, and Katherine T Andrews, and Donald L Gardiner, and John Ray, and Mark Kelly, and James S McCarthy
Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects.
January 2003, Drug metabolism and pharmacokinetics,
Copied contents to your clipboard!